Insider Transactions in Q3 2025 at Mineralys Therapeutics, Inc. (MLYS)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,367
-6.24%
|
$409,212
$36.19 P/Share
|
|
Sep 04
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
588,235
+50.0%
|
$14,705,875
$25.5 P/Share
|
|
Sep 04
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,176,470
+17.74%
|
$29,411,750
$25.5 P/Share
|
|
Aug 13
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,365
-10.9%
|
$136,380
$12.93 P/Share
|
|
Aug 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.74%
|
$6,349
$1.08 P/Share
|
|
Jul 30
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
59,925
-16.33%
|
$838,950
$14.9 P/Share
|
|
Jul 29
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
807
-0.42%
|
$11,298
$14.0 P/Share
|
|
Jul 28
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
12,946
-6.27%
|
$181,244
$14.04 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-10.4%
|
$159,124
$14.59 P/Share
|
|
Jul 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+5.49%
|
$6,349
$1.08 P/Share
|
|
Jul 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,758
-4.95%
|
$150,612
$14.45 P/Share
|
|
Jul 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,884
-1.84%
|
$222,376
$14.51 P/Share
|